NEJM· @NEJM · X·· 3 小时前精选AI 评分62
AI 导读
NEJM发布ANTHEM-UC 2期试验结果，每日一次口服icotrokinra用于中重度活动性溃疡性结肠炎，三个受试剂量组第12周临床缓解率均高于安慰剂。完整结果见 https://nej.md/4hLHjhO。
推荐理由
原文给出icotrokinra三个剂量组第12周临床缓解均优于安慰剂，读者可据此了解口服方案在中重度溃疡性结肠炎中的早期数据。
正文
In a phase 2 trial of once-daily oral icotrokinra for moderately to severely active ulcerative colitis, a clinical response at week 12 was more common with icotrokinra at each of three tested doses than with placebo. Full ANTHEM-UC trial results: https://nej.md/4hLHjhO
来源：NEJM · x.com